Add to Favourites
To login click here
This article discusses the need for medtech companies to protect their intellectual property (IP) and meet FDA and compliance-related requirements. It outlines key topics that companies should be aware of in their product development lifecycle, such as the ability to reverse engineer and claiming software uses necessary functional language. Additionally, it highlights the tension between breadth and abstraction levels in software patent draft.
